IRINOTECAN ACCORD irinotecan hydrochloride trihydrate 300 mg/15 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan accord irinotecan hydrochloride trihydrate 300 mg/15 ml concentrated injection vial

accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 300 mg - injection, concentrated - excipient ingredients: sodium hydroxide; lactic acid; hydrochloric acid; sorbitol; water for injections - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN ACCORD irinotecan hydrochloride trihydrate 500 mg/25 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan accord irinotecan hydrochloride trihydrate 500 mg/25 ml concentrated injection vial

accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 500 mg - injection, concentrated - excipient ingredients: hydrochloric acid; water for injections; lactic acid; sodium hydroxide; sorbitol - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN ALPHAPHARM irinotecan hydrochloride trihydrate 40 mg/2 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan alphapharm irinotecan hydrochloride trihydrate 40 mg/2 ml concentrated injection vial

alphapharm pty ltd - irinotecan hydrochloride trihydrate -

IRINOTECAN ALPHAPHARM irinotecan hydrochloride trihydrate 100 mg/5 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan alphapharm irinotecan hydrochloride trihydrate 100 mg/5 ml concentrated injection vial

alphapharm pty ltd - irinotecan hydrochloride trihydrate -

IRINOTECAN ALPHAPHARM irinotecan hydrochloride trihydrate 500mg/25mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan alphapharm irinotecan hydrochloride trihydrate 500mg/25ml concentrated injection vial

alphapharm pty ltd - irinotecan hydrochloride trihydrate -

IRINOTECAN BAXTER irinotecan hydrochloride trihydrate 100 mg/5 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan baxter irinotecan hydrochloride trihydrate 100 mg/5 ml concentrated injection vial

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: sodium hydroxide; lactic acid; water for injections; hydrochloric acid; sorbitol - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN BAXTER irinotecan hydrochloride trihydrate 40 mg/2 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan baxter irinotecan hydrochloride trihydrate 40 mg/2 ml concentrated injection vial

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: water for injections; lactic acid; sorbitol; hydrochloric acid; sodium hydroxide - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN BAXTER irinotecan hydrochloride trihydrate 300 mg/15 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan baxter irinotecan hydrochloride trihydrate 300 mg/15 ml concentrated injection vial

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 300 mg - injection, concentrated - excipient ingredients: lactic acid; sorbitol; hydrochloric acid; sodium hydroxide; water for injections - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Irinotecan Hydrochloride Concentrate for Soln for Inf 20mg/ml (5mL) Malta - English - Medicines Authority

irinotecan hydrochloride concentrate for soln for inf 20mg/ml (5ml)

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - irinotecan hydrochloride, trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 20 mg - antineoplastic agents

Irinotecan Hydrochloride Concentrate for Soln for Inf 20mg/ml (25mL) Malta - English - Medicines Authority

irinotecan hydrochloride concentrate for soln for inf 20mg/ml (25ml)

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - irinotecan hydrochloride, trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 20 mg - antineoplastic agents